HEPA_OUT_1 [2025-04-02 09:46:04 -0400] 3049 Bytes | 796 tokens | Cum: 796 tkns (9.95% of 8k)
==========================================================================

Booyah, my friends! It's already 9:46:03 AM on Wed Apr 02, 2025 -0400, and I've got my eyes locked on Hepion Pharmaceuticals (HEPA), pushing up to 0.658301 from 0.485. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Hepion Pharmaceuticals (HEPA)
IPO: 2014-02-07 (11 Years Ago)
Market Cap: $523,800
Shares Outstanding: 1,080,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Here's the first list of news for Hepion Pharmaceuticals:

C1 - Mar-14-25 12:15PM - Biotech Alert: Searches spiking for these stocks today
C2 - Mar-14-25 12:15PM 08:30AM - Hepion Pharmaceuticals Announces Reverse Stock Split
C3 - Jan-22-25 08:00AM - Hepion Pharmaceuticals Announces $9.0 Million Public Offering
C4 - Dec-11-24 08:00AM - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
C5 - Dec-05-24 08:30AM - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
C6 - Dec-02-24 08:00AM - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
C7 - Nov-11-24 08:00AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
C8 - Sep-04-24 09:25AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Prior AI Reports for HEPA:
1. 2025-04-01 – Score: 20 – Target: 0.6000 – Highs: – / – / –
company-faces-severe-decline-amidst-financial-distress

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Hepion Pharmaceuticals (HEPA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

HEPA_OUT_3 [2025-04-02 09:46:09 -0400] 1106 Bytes | 332 tokens | Cum: 1130 tkns (14.12% of 8k)
==========================================================================

Showing C2 (chunk 1 of 9): C2:
**Hepion Pharmaceuticals Announces Reverse Stock Split**
Date: Mar-14-25 12:15PM 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/14/3042959/0/en/Hepion-Pharmaceuticals-Announces-Reverse-Stock-Split.html

March 14, 2025 08:30 ET| Source:Hepion Pharmaceuticals, Inc.Hepion Pharmaceuticals, Inc.

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025

MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is exp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_OUT_5 [2025-04-02 09:46:10 -0400] 904 Bytes | 282 tokens | Cum: 1522 tkns (19.02% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF),...
A2 - 2025-03-25T13:48:08Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A3 - 2025-03-25T13:47:29Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A4 - 2025-03-25T13:48:08Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A5 - 2025-03-17T05:31:13Z - Upcoming Stock Splits This Week (March 17 to March 21) - Stay Invested...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HEPA_OUT_7 [2025-04-02 09:46:16 -0400] 1098 Bytes | 329 tokens | Cum: 1853 tkns (23.16% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - bioAffinity Technologies (NASDAQ:BIAF), CARISMA Therapeutics (NASDAQ:CARM)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44591128/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Reshape Lifesciences RSLS stock moved upwards by 488.1% to $2.12 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. bioAffinity Technologies BIAF stock increased by 236.5% to $0.87. The market value of their outstanding shares is at $13.6 million. As per the news, the Q4 earnings report came out yesterday. Alaunos Therapeutics TCRT shares moved upwards by 55.1% to $2.28. The market value of their outstanding shares is at $3.6 million. Nutex Health NUTX shares moved upwards by 53.55% to $72.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_OUT_9 [2025-04-02 09:46:17 -0400] 975 Bytes | 286 tokens | Cum: 2280 tkns (28.50% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-11T13:00:00Z - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
B2 - 2024-12-02T13:00:00Z - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
B3 - 2024-04-19T20:30:00Z - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
B4 - 2024-03-06T13:30:00Z - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
B5 - 2024-02-16T13:00:00Z - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
B6 - 2024-01-03T22:15:00Z - Hepion Pharmaceuticals to Present at NASH-TAG 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HEPA_OUT_11 [2025-04-02 09:46:20 -0400] 757 Bytes | 208 tokens | Cum: 2490 tkns (31.13% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/11/2995333/0/en/Hepion-Pharmaceuticals-Inc-Announces-Termination-of-Merger-Agreement-with-Pharma-Two-B-Ltd.htmlHepion Pharmaceuticals has terminated its merger agreement with Pharma Two B Ltd. and has withdrawn proposals for a special stockholder meeting. The company is continuing efforts to provide value from its drug candidate rencofilstat to shareholders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_OUT_13 [2025-04-02 09:46:22 -0400] 740 Bytes | 251 tokens | Cum: 2794 tkns (34.92% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Cons Fin Stmnts

HEPION PHARMACEUTICALS, INC. & SUBSIDIARIES

COND CONS BAL SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash $ 1,497,106 $ 14,785,880 Pr...

S2 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Cons Fin Stmnts

HEPION PHARMACEUTICALS, INC. & SUBSIDIARIES

COND CONS BAL SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash $ 1,497,106 $ 14,785,880 Pr...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HEPA_OUT_15 [2025-04-02 09:46:29 -0400] 1098 Bytes | 344 tokens | Cum: 3140 tkns (39.25% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART IFINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Current assets: Cash $ 1,497,106 $ 14,785,880 Prepaid expenses 1,433,186 2,701,960 Related party receivable 600,000 Total current assets 3,530,292 17,487,840 Property and equipment, net 29,487 Right-of-use assets 118,301 212,878 Other assets 66,505 364,192 Total assets $ 3,715,098 $ 18,094,397 Liabilities and Stockholders Equity Current liabilities: Accounts payable $ 186,259 $ 2,348,829 Accrued expenses 306,000 2,439,351 Operating lease liabilities, current 117,952 115,916 Notes payable, current 2,105,753 Short-term portion of contingent consideration 386,000 Total current liabilities 2,715,964 5,290,096 Contingent consideration, non-current 1,634,000 Oper

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_OUT_17 [2025-04-02 09:46:41 -0400] 4153 Bytes | 1174 tokens | Cum: 4478 tkns (55.97% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 2,339,236 | Perf Month: -88.60% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 1.94M | Perf Quarter: -97.31% | Short Float: 14.91% | ROE: -288.27% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 24.07 | Index: - | Short Ratio: 0.08 | ROI: - |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 22.12 | Market Cap: 0.62M | Short Interest: 0.16M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.64 | Shs Outstand: 1.08M | Beta: 1.85 | EPS Surprise: -17.54% |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: -62.48% | Shs Float: 1.07M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -89.69% | Inst Own: 2.89% | Sales past 5Y: - | Earnings: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -97.95% | Insider Own: 0.48% | Employees: - | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: -15.45% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -4865948.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.6429
Average Volume: 4358830.36
30-Day High: 5.64
30-Day Low: 0.4299

[Detailed Financials: Q3 2024]
- Total Assets: $3,715,098.0
- Total Liabilities: $4,121,783.0
- Total Equity: $-406,685
- Current Assets: $3,530,292.0
- Current Liabilities: $2,715,964.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.72

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $14,495,592.0

[Detailed Financials: Q2 2024]
- Total Assets: $6,010,164.0
- Total Liabilities: $2,448,334.0
- Total Equity: $3,561,830.0
- Current Assets: $5,482,409.0
- Current Liabilities: $975,634

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.68

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-14,433,832.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

HEPA_OUT_19 [2025-04-02 09:46:44 -0400] 676 Bytes | 167 tokens | Cum: 4927 tkns (61.59% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

HEPA_IN_21 [2025-04-02 09:46:45 -0400] 126 Bytes | 29 tokens | Cum: 5030 tkns (62.88% of 8k)
==========================================================================

====================================
[2025-04-02 09:46:45] # Analysis Completed
Elapsed Time: 42.02 seconds